Abstract:Background The diagnosis of and distinction between acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) have long been based on blast counts, with the presence of ≥20% myeloblasts in marrow or peripheral blood required to define AML in World Health Organization classification. Until 2001, blast counts greater than 30% had been used to diagnose AML by the original French-American-British classification system. However, the 2022 International Consensus Classification proposed a new combined category of MDS/AML with 10-19% blasts. Here we report the real-world treatment pattern and outcomes of AML and high-risk MDS patients at an academic institution in the United States, with specific attention to the blast burden at initial disease diagnosis to validate accuracy and limitation of this new proposed change. Methods This is a retrospective study conducted at UCLA Health encompassing all diagnoses of AML and MDS made at academic campus and community practices. We evaluated adult patients with a diagnosis with either AML or MDS from 1/1/2016-7/31/2022. For patients with more than one bone marrow biopsy on record, we recognized the date of diagnosis of MDS or AML with a blast burden ≥ 10% by immunohistochemistry or flow cytometry as the first bone marrow biopsy. In light of the changing diagnostic definitions, we analyzed patients by cohorts of MDS/AML with 10-19% blasts, AML low-blast with 20-29% blasts, and AML high-blast ≥ 30% blasts. Survival analysis by blast count at diagnosis was calculated by Kaplan-Meier estimates. A Multivariable Cox proportional hazard model was used to model survival outcomes by blast cohort, ELN risk 2022, response to first treatment, and receipt of allogeneic hematopoietic cell transplantation (HCT). Results There were 422 patients at UCLA Health with a diagnosis of AML or MDS included in our analysis with blast burden ≥ 10%. Patient demographics are shown in Table 1. Median age at diagnosis for MDS/AML, AML low-blast and AML high-blast cohorts is 67, 66 and 64 respectively (p=0.02). Thirty two (66.7%) patients in MDS/AML cohort received non-intensive first line treatment, whereas 202 (67.8%) AML high-blast patients received intensive first treatment. For AML low-blast patients, 37 (48.7%) received intensive treatment, and 29 (38.2%) received non-intensive treatment. More patients with AML (either low- or high-blast) underwent allogeneic HCT compared to MDS/AML patients. By Kaplain Meier analysis (KM) using blast counts as the sole predictor (Figure 1), no significant difference in OS when following patients for up to five years from diagnosis (p=0.0985) was seen. The p-value for two-way KM comparisons for MDS/AML vs. AML low-blast is 0.9682, and for AML low-blast vs. AML high-blast is 0.112. By multivariable analysis, ELN Risk 2022 (p<.0001), allogeneic HCT (p<.0001), and Complete Response to initial treatment (p<.0001) were predictive of OS, but blast percentages were not (p=0.56). Conclusion In our study, we found similar survival outcomes in high-risk MDS and AML patients regardless of initial blast counts at diagnosis. Though not statistically significant, MDS/AML and AML with low-blast burden appear to share more similar outcomes. This could be due to increased secondary AML seen in the low-blast cohort, and implies potentially different disease biology between high blast burden AML and AML with dysplastic changes. With this observation, we emphasize caution on simply using ICC 2022 to apply traditional AML therapy to the new MDS/AML category. Both WHO and ICC classification in 2022 reflects the increasing potential of molecular profiling to subtype these diseases, which will be the future direction. Rather than moving the blast count cutoff between AML and MDS, it is more critical to emphasize inclusion of high-risk MDS patients on all AML clinical trials and perhaps the converse for low blast burden AML with dysplastic changes, which might allow better understanding of response to therapy and disease biology.

Clinical and Biological Characteristics of Acute Myeloid Leukemia with 20-29% Blasts: a Retrospective Single-Center Study

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Real‐world Data of Chronic Myelomonocytic Leukemia: A Chinese Single‐center Retrospective Study

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Cytogenetic Profile of De Novo Acute Myeloid Leukemia: a Study Based on 1432 Patients in a Single Institution of China

Reconsidering the Significance of Blast Cut-Offs in Differentiating between MDS and AML Biology

[Clinical Study of Patients with Myelodysplastic Syndrome Transformed into Acute Myeloid Leukemia].

Clinical Significance Of Myeloblasts Percentage In The De Novo Acute Myeloid Leukemia With Erythroid Hyperplasia

Transformation of myelodysplastic syndromes into acute myeloid leukemias

[Clinical and Cytogenetical Study on Subacute Myeloid Leukemia in Myelodysplastic Syndromes].

[Characteristics and Prognosis in Adult Acute Myeloid Leukemia Patients with MLL Gene Rearrangements].

A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1‐negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia‐related

Prognostic Significance of the Frequencies of Bone Marrow Lymphocyte Subsets in Adult Acute Myeloid Leukemia at Diagnosis.

[Survival and Prognosis of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome]

[Analysis of clinical features of patients with de novo primary acute myeloid leukemia and various chromosomal karyotypes]

[A New Prognostic Stratification for Patients with Acute Myeloid Leukemia].